BACKGROUND: It is generally accepted that patients with breast cancer metastases have very poor survival. Metastatic breast cancer patients can be considered a heterogeneous population with a varied clinical course, which underscores the need for accurate prediction of survival based on prognostic factors. The purpose of the present study was to identify factors related to survival in breast cancer patients after diagnosis with metastatic disease. POPULATIONS AND METHODS: A total of 557 patients with breast cancer metastasis diagnosis seen at one large urban practice have been followed up between 1 January, 1999 and 30 June, 2010. Demographic, tumor characteristics, clinical factors as predictors of survival were analyzed using log-rank test and Cox regression model. RESULTS: The median survival length was 39 months (range 1-138 months) with 154 (27.7%) alive and 403 (72.3%) dead at the end of follow-up period. This study demonstrated that a history of hypertension, ER/PR status, HER2 status, metastasis-free interval, metastatic location (including brain, bone and liver), and BMI at diagnosis with metastatic breast cancer were the most relevant prognostic factors for survival after metastatic disease diagnosis. CONCLUSION: Findings of this study may form a foundation for the growing corpus of knowledge explaining the outcome differences in treatment of patients with metastatic breast cancer, potentially helping to create tailored counseling and personalized treatment approaches for this vulnerable group.
BACKGROUND: It is generally accepted that patients with breast cancer metastases have very poor survival. Metastatic breast cancerpatients can be considered a heterogeneous population with a varied clinical course, which underscores the need for accurate prediction of survival based on prognostic factors. The purpose of the present study was to identify factors related to survival in breast cancerpatients after diagnosis with metastatic disease. POPULATIONS AND METHODS: A total of 557 patients with breast cancer metastasis diagnosis seen at one large urban practice have been followed up between 1 January, 1999 and 30 June, 2010. Demographic, tumor characteristics, clinical factors as predictors of survival were analyzed using log-rank test and Cox regression model. RESULTS: The median survival length was 39 months (range 1-138 months) with 154 (27.7%) alive and 403 (72.3%) dead at the end of follow-up period. This study demonstrated that a history of hypertension, ER/PR status, HER2 status, metastasis-free interval, metastatic location (including brain, bone and liver), and BMI at diagnosis with metastatic breast cancer were the most relevant prognostic factors for survival after metastatic disease diagnosis. CONCLUSION: Findings of this study may form a foundation for the growing corpus of knowledge explaining the outcome differences in treatment of patients with metastatic breast cancer, potentially helping to create tailored counseling and personalized treatment approaches for this vulnerable group.
Authors: Donald Courtney; Matthew G Davey; Brian M Moloney; Michael K Barry; Karl Sweeney; Ray P McLaughlin; Carmel M Malone; Aoife J Lowery; Michael J Kerin Journal: Ir J Med Sci Date: 2022-01-25 Impact factor: 1.568
Authors: Lanell M Peterson; Janet O'Sullivan; Qian Vicky Wu; Alena Novakova-Jiresova; Isaac Jenkins; Jean H Lee; Andrew Shields; Susan Montgomery; Hannah M Linden; Julie Gralow; Vijayakrishna K Gadi; Mark Muzi; Paul Kinahan; David Mankoff; Jennifer M Specht Journal: J Nucl Med Date: 2018-05-10 Impact factor: 10.057
Authors: Yizhuo Kelly Gao; Markus Kuksis; Badr Id Said; Rania Chehade; Alex Kiss; William Tran; Faisal Sickandar; Arjun Sahgal; Ellen Warner; Hany Soliman; Katarzyna J Jerzak Journal: Oncologist Date: 2021-09-21
Authors: Nigel T Brockton; Stephanie J Gill; Stephanie L Laborge; Alexander H G Paterson; Linda S Cook; Hans J Vogel; Carrie S Shemanko; David A Hanley; Anthony M Magliocco; Christine M Friedenreich Journal: BMC Cancer Date: 2015-07-10 Impact factor: 4.430
Authors: Markus Kuksis; Yizhuo Gao; William Tran; Christianne Hoey; Alex Kiss; Adam S Komorowski; Aman J Dhaliwal; Arjun Sahgal; Sunit Das; Kelvin K Chan; Katarzyna J Jerzak Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300